A Basic Introduction To Nootropics

In China, neurological medications have been one of the fastest-growing categories of drugs in recent years. In 2002, these drugs accounted for 5.9% of the total pharmaceutical market, with total sales increasing by 9.4%.

With increasing urbanization and an aging population, China's elderly population has surpassed 120 million, and the incidence of geriatric diseases, particularly mental illnesses, has been increasing year by year. Rising incomes have also led to a higher demand for quality of life among the elderly. This trend has significantly increased demand for medications to treat mental illnesses, such as Alzheimer's disease. The WHO drug classification combines psychotropics and nootropics into one category. We briefly analyze the development trends of this drug category using clinical medication data from over 300 key hospitals in China, collected by the Chinese Pharmaceutical Association. The overall market size of this drug class is approximately 1.22 billion yuan. In 2002, sales revenue increased by only 5.0%, while sales volume increased by 11.2%. This failure to keep pace with sales volume is primarily due to the significant price drops experienced by several key products in this class, such as piracetam, cobalt amide, and ginkgo biloba leaves, in 2002 due to bidding. Ginkgo biloba preparations hold the largest market share, exceeding one-third. Gangliosides and cobalt amides together account for nearly one-third. Piracetam and other "racetam" drugs hold nearly 10% of the market share, while the remaining drugs each hold less than 5%.

Currently, there are over 20 ginkgo biloba manufacturers and over 70 piracetam manufacturers, all of which have entered a price-based competition phase, resulting in increasingly diluted profits. Among first-line drugs, with the exception of ginkgo biloba preparations, which maintained robust growth, other drugs experienced sluggish growth. Piracetam, a traditional drug, suffered a significant setback in tendering and procurement, and has been unable to recover. Aniracetam sales also declined as a result, with the sharp decline in racetam-based drugs being the primary factor contributing to the decline in market growth within this drug category. However, an examination of several new second-line drugs reveals significant potential within this category. Several new second-line drugs, such as huperzine A and donepezil, have seen significant growth, demonstrating rapid development. As more new dementia treatments enter the market, market potential will further expand, while also facing increasing competitive pressure.